Correction of peroxidation of lipids with upadacitinib, a Janus kinase 1 inhibitor, in patients with true eczema

Objective. To study the effect of upadacitinib (UPA), a Janus kinase inhibitor 1 kinase, on the status of peroxidation of lipids (POL) and the antioxidant system in patients with true eczema.

Subjects and methods. The investigation involved 64 patiens (43 males and 21 females) with true eczema (the mean age was 58.5±3.4 years). The patients were randomized into 2 groups: 1) 33 patients who received basic drug therapy (BDT); 2) 31 patients who received the Janus kinase 1 inhibitor UPA 15 mg/day during 2 months. The components of the antioxidant system and the state of POL were determined by enzyme immunoassay.

Results. After 2 months of therapy, Group 1 showed no statistically significant changes in the analyzed parameters from the baseline level (p>0.05). In Group 2, the total oxidative capacity of blood reduced by 1.27 tines; the level of oxidized low-density lipoproteins decreased by 1.28 times; the total antioxidant activity of blood increased by 1.24 times; the level of superoxidase dismutase increased by 1.43 times (p < 0.001 for all values).

Conclusion. The combined use of BDT and the JAK1 inhibitor UPA in patients with true eczema contributed to a statistically significant decline in the oxidative capacity of blood and POL products along with the enhanced antioxidant activity of blood.